TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 MARKET ATTRACTIVE ANALYSIS 19

1.1.1 GLOBAL HYALURONIC ACID MARKET, BY GRADE 19

1.1.2 GLOBAL HYALURONIC ACID, BY APPLICATION 20

1.1.3 GLOBAL HYALURONIC ACID, BY END USER 21

2 MARKET INTRODUCTION
2.1 DEFINITION 22

2.2 SCOPE OF THE STUDY 22

2.3 MARKET STRUCTURE 22

3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS 23

3.2 PRIMARY RESEARCH 24

3.3 SECONDARY RESEARCH 25

3.4 MARKET SIZE ESTIMATION 26

3.5 FORECAST MODEL 27

3.6 LIST OF ASSUMPTIONS 27

4 MARKET DYNAMICS
4.1 INTRODUCTION 28

4.2 DRIVERS 29

4.2.1 INCREASING APPLICATION OF HYALURONIC ACID IN COSMETIC & PERSONAL CARE PRODUCTS 29

4.2.2 INCREASING NUMBER OF COSMETIC SURGERIES 30

4.2.3 EXTENSIVE USE OF HYALURONIC ACID IN THE TREATMENT OF OSTEOARTHRITIS AND DRY EYE 31

4.3 RESTRAINTS 32

4.3.1 AVAILABILITY OF SUBSTITUTES 32

4.4 OPPORTUNITY 33

4.4.1 EXTENSIVE RESEARCH AND DEVELOPMENT ASSOCIATED WITH HYALURONIC ACID 33

4.5 TREND 34

4.5.1 USE OF HYALURONIC ACID AS AN ANIMAL SUPPLEMENT 34

5 MARKET FACTOR ANALYSIS
5.1 SUPPLY CHAIN ANALYSIS 35

5.1.1 RAW MATERIAL SUPPLIERS 35

5.1.2 HYALURONIC ACID PRODUCERS 36

5.1.3 DISTRIBUTION & SALES CHANNEL 36

5.1.4 END USERS 36

5.2 PORTER'S FIVE FORCES MODEL 37

5.2.1 THREAT OF NEW ENTRANTS 37

5.2.2 INTENSITY OF RIVALRY 38

5.2.3 THREAT OF SUBSTITUTES 38

5.2.4 BARGAINING POWER OF SUPPLIERS 38

5.2.5 BARGAINING POWER OF BUYERS 38

6 GLOBAL HYALURONIC ACID MARKET, BY GRADE
6.1 OVERVIEW 39

6.2 COSMETIC GRADE 41

6.3 PHARMACEUTICAL GRADE 41

6.4 FOOD GRADE 42

7 GLOBAL HYALURONIC ACID MARKET, BY APPLICATION
7.1 OVERVIEW 43

7.2 AESTHETICS 44

7.3 OSTEOARTHRITIS 45

7.4 PHARMACEUTICAL API 46

7.5 COSMETICS 46

7.6 DIETARY SUPPLEMENTS 47

7.7 OPHTHALMOLOGY 48

7.8 OTHERS 48

8 GLOBAL HYALURONIC ACID MARKET, BY END USER
8.1 OVERVIEW 49

8.2 PHARMACEUTICAL INDUSTRY 51

8.3 DERMATOLOGY CLINICS & COSMETIC SURGERY CENTERS 52

8.4 FOOD INDUSTRY 52

8.5 PERSONAL CARE 53

8.6 OTHERS 53

9 GLOBAL HYALURONIC ACID MARKET, BY REGION
9.1 OVERVIEW 54

9.2 NORTH AMERICA 57

9.2.1 US 61

9.2.2 CANADA 63

9.3 EUROPE 66

9.3.1 FRANCE 70

9.3.2 GERMANY 73

9.3.3 UK 75

9.3.4 SPAIN 78

9.3.5 ITALY 80

9.3.6 RUSSIA 83

9.3.7 BELGIUM 85

9.3.8 POLAND 88

9.3.9 REST OF EUROPE 90

9.4 ASIA-PACIFIC 93

9.4.1 CHINA 97

9.4.2 JAPAN 100

9.4.3 INDIA 102

9.4.4 SOUTH KOREA 105

9.4.5 AUSTRALIA 107

9.4.6 THAILAND 110

9.4.7 INDONESIA 112

9.4.8 REST OF ASIA-PACIFIC 115

9.5 LATIN AMERICA 118

9.5.1 BRAZIL 122

9.5.2 MEXICO 125

9.5.3 ARGENTINA 127

9.5.4 REST OF LATIN AMERICA 130

9.6 MIDDLE EAST & AFRICA 133

9.6.1 SAUDI ARABIA 137

9.6.2 UAE 140

9.6.3 TURKEY 142

9.6.4 SOUTH AFRICA 145

9.6.5 ISRAEL 147

9.6.6 REST OF MIDDLE EAST AND AFRICA 150

10 COMPETITIVE LANDSCAPE
10.1 COMPETITIVE OVERVIEW 153

10.2 GLOBAL MARKET STRATEGY ANALYSIS 153

10.3 KEY DEVELOPMENTS 153

10.4 COMPETITIVE BENCHMARKING 154

11 COMPANY PROFILES
11.1 ALLERGAN 155

11.1.1 COMPANY OVERVIEW 155

11.1.2 FINANCIAL OVERVIEW 156

11.1.3 PRODUCTS OFFERED 156

11.1.4 KEY DEVELOPMENTS 157

11.1.5 SWOT ANALYSIS 157

11.1.6 KEY STRATEGIES 157

11.2 CONTIPRO A.S. 158

11.2.1 COMPANY OVERVIEW 158

11.2.2 FINANCIAL OVERVIEW 158

11.2.3 PRODUCTS OFFERED 158

11.2.4 KEY DEVELOPMENTS 158

11.2.5 SWOT ANALYSIS 159

11.2.6 KEY STRATEGIES 159

11.3 SYMATESE GROUP 160

11.3.1 COMPANY OVERVIEW 160

11.3.2 FINANCIAL OVERVIEW 160

11.3.3 PRODUCTS OFFERED 160

11.3.4 KEY DEVELOPMENTS 160

11.3.5 SWOT ANALYSIS 161

11.3.6 KEY STRATEGIES 161

11.4 ZHONGLAN INDUSTRY CO., LTD 162

11.4.1 COMPANY OVERVIEW 162

11.4.2 FINANCIAL OVERVIEW 162

11.4.3 PRODUCTS OFFERED 162

11.4.4 KEY DEVELOPMENTS 162

11.4.5 SWOT ANALYSIS 163

11.4.6 KEY STRATEGIES 163

11.5 ALTERGON ITALIA SRL 164

11.5.1 COMPANY OVERVIEW 164

11.5.2 FINANCIAL OVERVIEW 164

11.5.3 PRODUCTS OFFERED 164

11.5.4 KEY DEVELOPMENTS 164

11.5.5 SWOT ANALYSIS 165

11.5.6 KEY STRATEGIES 165

11.6 FIDIA FARMACEUTICI S.P.A. 166

11.6.1 COMPANY OVERVIEW 166

11.6.2 FINANCIAL OVERVIEW 166

11.6.3 PRODUCTS OFFERED 166

11.6.4 KEY DEVELOPMENTS 166

11.6.5 SWOT ANALYSIS 167

11.6.6 KEY STRATEGIES 167

11.7 BIOIBERICA S.A.U. 168

11.7.1 COMPANY OVERVIEW 168

11.7.2 FINANCIAL OVERVIEW 168

11.7.3 PRODUCTS OFFERED 168

11.7.4 KEY DEVELOPMENTS 168

11.7.5 SWOT ANALYSIS 169

11.7.6 KEY STRATEGIES 169

11.8 KEWPIE CORPORATION 170

11.8.1 COMPANY OVERVIEW 170

11.8.2 FINANCIAL OVERVIEW 170

11.8.3 PRODUCTS OFFERED 171

11.8.4 KEY DEVELOPMENTS 171

11.8.5 SWOT ANALYSIS 171

11.8.6 KEY STRATEGIES 171

11.9 SEIKAGAKU CORPORATION 172

11.9.1 COMPANY OVERVIEW 172

11.9.2 FINANCIAL OVERVIEW 173

11.9.3 PRODUCTS OFFERED 173

11.9.4 KEY DEVELOPMENTS 174

11.9.5 SWOT ANALYSIS 174

11.9.6 KEY STRATEGIES 174

11.10 ANIKA THERAPEUTICS 175

11.10.1 COMPANY OVERVIEW 175

11.10.2 FINANCIAL OVERVIEW 175

11.10.3 PRODUCTS OFFERED 176

11.10.4 KEY DEVELOPMENTS 176

11.10.5 SWOT ANALYSIS 176

11.10.6 KEY STRATEGIES 176

12 APPENDIX
12.1 REFERENCES 177

12.2 RELATED REPORTS 178